Trial Profile
A retrospective trial of ruxolitinib as salvage-therapy for graft-versus-host disease (GVHD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 06 Dec 2016 Results of long-term follow-up, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 22 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology